Provectus Biopharmaceuticals Stock Net Asset
PVCTDelisted Stock | USD 0.11 0.00 0.00% |
Provectus Biopharmaceuticals fundamentals help investors to digest information that contributes to Provectus Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of Provectus OTC Stock. The fundamental analysis module provides a way to measure Provectus Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Provectus Biopharmaceutica otc stock.
Provectus |
Provectus Biopharmaceuticals OTC Stock Net Asset Analysis
Provectus Biopharmaceutica's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Provectus Biopharmaceutica Net Asset | 3.51 M |
Most of Provectus Biopharmaceutica's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Provectus Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Provectus Biopharmaceuticals has a Net Asset of 3.51 M. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Provectus Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Provectus Biopharmaceutica's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Provectus Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Provectus Biopharmaceutica by comparing valuation metrics of similar companies.Provectus Biopharmaceutica is currently under evaluation in net asset category among its peers.
Provectus Fundamentals
Return On Asset | -1.85 | ||||
Operating Margin | (4.77) % | ||||
Current Valuation | 46.73 M | ||||
Shares Outstanding | 419.55 M | ||||
Shares Owned By Insiders | 3.69 % | ||||
Shares Owned By Institutions | 0.04 % | ||||
Number Of Shares Shorted | 1.82 M | ||||
Price To Earning | (0.48) X | ||||
Price To Book | 5.44 X | ||||
Price To Sales | 55.94 X | ||||
EBITDA | (4.56 M) | ||||
Net Income | (5.54 M) | ||||
Cash And Equivalents | 84.27 K | ||||
Total Debt | 2.29 M | ||||
Debt To Equity | 0.25 % | ||||
Current Ratio | 0.27 X | ||||
Book Value Per Share | (0.02) X | ||||
Cash Flow From Operations | (1.01 M) | ||||
Short Ratio | 0.47 X | ||||
Earnings Per Share | (0.01) X | ||||
Target Price | 3.5 | ||||
Beta | 0.5 | ||||
Market Capitalization | 44.47 M | ||||
Total Asset | 3.51 M | ||||
Retained Earnings | (180.8 M) | ||||
Working Capital | 10.6 M | ||||
Current Asset | 14.72 M | ||||
Current Liabilities | 4.12 M | ||||
Z Score | -59.7 | ||||
Net Asset | 3.51 M |
About Provectus Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Provectus Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Provectus Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Provectus Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Provectus OTC Stock
If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Transaction History View history of all your transactions and understand their impact on performance | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |